Research demonstrates that small interfering RNA targeting protein Z-dependent protease inhibitor enhances hemostasis in mice deficient in von Willebrand factor and Factor X. This study could pave the way for new therapeutic strategies in bleeding disorders.

A case report details comprehensive dental management under general anesthesia for a pediatric patient with type 3 von Willebrand disease. This study highlights the challenges and considerations in treating dental issues in patients with bleeding disorders.

A recent study highlights persistent gingival bleeding after dental scaling as a potential diagnostic indicator for von Willebrand disease. This finding could enhance early detection and management of the condition.

FDA classifies the von Willebrand factor assay into class II, establishing special controls to ensure safety and effectiveness. This classification aims to enhance regulatory oversight for devices related to von Willebrand disease.

If you’re looking for a sign that biotech’s IPO renaissance remains on track then the pair of upsized Nasdaq listings on Friday morning is a good place to start. | "We want to develop those programs as far as we can ourselves,” Seaport CEO Daphne Zohar told Fierce. The IPO funds are expected to help finance a phase 3 study in Glanzmann thrombasthenia, as well as an ongoing phase 2 trial in another bleeding disorder called Factor VII deficiency. Meanwhile, Hemab wants to push its monovalent antibody, HMB-002, through a phase 1/2 study for von Willebrand disease, another genetic disorder that impacts blood clotting. Seaport Therapeutics Hemab Therapeutics IPO biotech IPO Biotech Zohar co-founded Karuna Therapeutics, the neuroscience biotech bought by Bristol Myers Squibb for $14 billion to acquire the schizophrenia drug that would hit the market as Cobenfy. When asked by Fierce why Seaport hadn’t also opted for a Big Pharma acquisition, Zohar suggested that companies try and keep both options open. Both depression-focused Seaport Therapeutics and clotting company Hemab Therapeutics had been priming investors earlier this week to expect IPOs of around the $180 million range. But the companies significantly overshot their targets. Boston-based Seaport sold nearly 14.2 million shares for its offering—flying past the 11.8 million shares that the company had been expecting as recently as Monday. With the shares priced at $18 apiece, it means the biotech will rake in $254.9 million in gross proceeds from the IPO. Seaport’s stock began trading on the Nasdaq this morning under the ticker “SPTX.” It was joined by another biotech entrant in the form of Hemab. Like Seaport, Hemab had been banking on an IPO of around $180 million, but the end result has come out above $300 million, according to an April 30 release.